Assays for biofluids, such as CSF and plasma, have shown great promise for measuring amyloid and tau as lower cost in-vivo biomarkers for early AD detection.17 A gold-standard for in-vitro measurements of CSF amyloid beta has been the ELISA (enzyme linked immunosorbent sandwich assay).18 Ultrasensitive assays for measuring amyloid beta and tau AD biomarkers include electrochemiluminescence assay (ECLIA)19,20, single molecule array (SIMOA)21,22, mass spectrometry23,24, among others. The gene discussed is MAPT; the disease is Alzheimer disease.